Have you gone to giving Epo SC?

HEMODIALYSIS — EPO given subcutaneously three times a week will maintain the hematocrit at the same level and at a lower dose than intravenous EPO. In almost all published studies, subcutaneous administration is associated with a 25 to 50 percent EPO dose reduction [1-8]. As an example, an unblinded 26 week study evaluated 208 chronic hemodialysis patients who were randomized to either subcutaneous or intravenous therapy; the target hematocrit was 30 to 33 percent [6]. The average weekly dose of EPO was 32 percent less for those randomly assigned to the subcutaneous regimen (94 versus 150 U/kg). The average hematocrit and hemoglobin levels were similar for both groups, and only one patient randomized to subcutaneous therapy withdrew because of pain.
Continued...
http://www.uptodate.com/patients/con...GBBcyvkvnb9klI


Subcutaneous versus intravenous administration of erythropoietin improves its efficiency for the treatment of anaemia in haemodialysis patients
http://ndt.oxfordjournals.org/cgi/co...ct/10/supp6/40

Urinary loss of erythropoietin after intravenous versus subcutaneous epoetin-beta in preterm infants.

Langer J, Obladen M, Dame C.
Klinik für Neonatologie, Campus Virchow-Klinikum, Charité-Universitätsmedizin, Berlin, Germany.
Hematopoietic and non-hematopoietic effects of recombinant erythropoietin (Epo) given to preterm infants are controversially discussed. Because renal loss of Epo was significantly higher after intravenous versus subcutaneous Epoetin-beta administration, we suggest a reconsideration of whether subcutaneous recombinant Epo is more efficient and safer because of lower peaks of circulating Epo.
PMID: 18410782 [PubMed - indexed for MEDLINE]